Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Net Income towards Common Stockholders (2024 - 2025)

Maze Therapeutics has reported Net Income towards Common Stockholders over the past 2 years, most recently at -$34.6 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 514.43% to -$34.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$131.1 million through Dec 2025, down 196.47% year-over-year, with the annual reading at -$131.1 million for FY2025, 3950.81% down from the prior year.
  • Net Income towards Common Stockholders was -$34.6 million for Q4 2025 at Maze Therapeutics, down from -$30.1 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $13.9 million in Q2 2024 and troughed at -$34.6 million in Q4 2025.